Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Ovarian Neoplasms × durvalumab × Clear all

Phase

Status

Completed 9 Active not recruiting 5 Terminated 3 Recruiting 2 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Small Cell Lung Carcinoma 4 Carcinoma, Hepatocellular 4 Cholangiocarcinoma 2 Biliary Tract Neoplasms 2 Urinary Bladder Neoplasms 1 Respiratory Tract Neoplasms 1 Rare Tumour 1 Pathologic Complete Response 1 Pancoast Syndrome 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Locally Advanced Rectal Carcinoma 1 Liver Neoplasms 1 Gallbladder Neoplasms 1 Gallbladder Cancer Unresectable 1 Bile Duct Neoplasms 1

Interventions

Bevacizumab 8 Paclitaxel 6 fluzoparib 5 Carboplatin 5 olaparib 3 famitinib 2 apatinib 2 Topotecan 2 Oxaliplatin 2 Drug Therapy 2 Cisplatin 2 trastuzumab deruxtecan 1 trametinib 1 niraparib 1 montelukast 1 liposomal doxorubicin 1 fludarabine 1 durvalumab 1 dalpiciclib 1 dabrafenib 1 bemarituzumab 1 aldesleukin 1 Ultrasonography, Doppler 1 Therapeutics 1 Tablets 1 Surgical Procedures, Operative 1 Sensitivity Training Groups 1 Saline Solution 1 SHR-1701 1 Poly A 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06650709 2024-10-23

NEOCATS

British Columbia Cancer Agency

Phase 2 Not yet recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡